{'fraction_non_alphanumeric': 0.030927835051546393, 'fraction_numerical': 0.012027491408934709, 'mean_word_length': 5.940476190476191, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
[Antagonists of platelet P2 receptors: achievements, problems, and prospects].

This review is focused on the participation of P2 receptors in platelet aggregation as a first step of arterial thrombosis. Pharmacological characteristics of three subtypes of P2 receptors and their role in platelet aggregation are described. Advantages and disadvantages of widely used thienopyridine antiplatelet drugs (ticlopidine, clopidogrel)--blockers of platelet P2Y12-receptors--are considered. Characteristics of new promising antiplatelet drugs acting on platelet P2 receptors are presented.